TEDIZOLID PHOSPHATE

USDailyMed:Tedizolid J01XX11(WHO) CA:℞-onlyUS:℞-onlyEU:Rx-only (5R)-3-{3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl]phenyl}-5-(hydroxymethyl)-1,3-oxazolidin-2-one 856866-72-3NPhosphate:856867-55-5Y 11234049 DB09042Y 9409096Y 97HLQ82NGLPhosphate:O7DRJ6R4DWY D09685YPhosphate:D09686Y CHEBI:82717Y ChEMBL1257051N DTXSID10234975 Interactive image O=C4O[C@H](CN4c3cc(F)c(c1ccc(nc1)c2nn(nn2)C)cc3)CO InChI=1S/C17H15FN6O3/c1-23-21-16(20-22-23)15-5-2-10(7-19-15)13-4-3-11(6-14(13)18)24-8-12(9-25)27-17(24)26/h2-7,12,25H,8-9H2,1H3/t12-/m1/s1YKey:XFALPSLJIHVRKE-GFCCVEGCSA-NY Tedizolid, sold under the brand nameSivextro(by Merck) is anoxazolidinone-classantibiotic.‍‍‍‍‍‍​​​‍​​​​​​ Tedizolid phosphate is aphosphate esterprodrug of the active compound tedizolid. It was developed byCubist Pharmaceuticals, following acquisition ofTrius Therapeutics(originator: Dong-A Pharmaceuticals), and is marketed for the treatment of acute bacterial skin and skin structure infections (also known ascomplicated skin and skin-structure infections(cSSSIs)).[medical citation needed] The most common side effects includenausea(feeling sick),headache,diarrheaandvomiting.These side effects were generally of mild or moderate severity. Tedizolid was approved for medical use in the United States in June 2014,and authorized for medical use in the European Union in March 2015.Tedizolid phosphate is a therapeutic alternative on theWorld Health Organization's List of Essential Medicines.